Helus Pharma Inc.
HELPNASDAQHealthcare
Research Update
HLP003 Achieves Statistically Significant Phase 3 Efficacy with Sustained Benefits Through Week 12, Supporting Higher Development Success Probability
- Published
- PDF Length
- 13-page PDF
- Coverage
- Independent Research
Summary
Helus Pharma’s first pivotal Phase 3 trial of HLP003 met its primary and key secondary endpoints in adults with moderate to severe major depressive disorder who continued their existing antidepressant. The results strengthen the efficacy case for an intermittent add-on treatment. Three treatment-related serious adverse events keep safety in focus as the program advances toward the second pivotal trial.

Key Development
APPROACH included 222 participants in its intent-to-treat analysis. At Week 6, depression scores on the Montgomery–Åsberg Depression Rating Scale (MADRS) fell 19.5 points with HLP003 and 11.9 points with placebo, a 7.6-point difference (p < 0.0001). The difference emerged by Day 2 (5.0 points) and persisted through Week 12 (7.0 points). At Week 6, response was 56.3% versus 28.2%, and remission was 50.9% versus 18.2%, for HLP003 and placebo, respectively.
Helus reported three treatment-related serious adverse events. On the results webcast, management described one suicide attempt and two events involving depression. Most adverse events were mild to moderate, transient, and concentrated on dosing days.
Impact on Thesis
The readout provides pivotal evidence of symptom improvement after two administrations of HLP003 three weeks apart. The Week 12 result supports a potential advantage for intermittent dosing. Longer follow-up will help determine how often patients relapse and need retreatment, which also affects clinic capacity and treatment costs.
The placebo-adjusted effect was numerically larger than in selected historical trials of other depression treatments. Differences in study populations, control arms, dosing schedules, and assessment timing limit comparisons of relative efficacy. The investment case still depends on EMBRACE confirming efficacy, regulators assessing the full safety data, and Helus securing the capital it needs for development and potential commercialization.
Estimate / Assumption Changes
AER raises its modeled probability of success for HLP003 from 60% to 75%, reflecting the primary and key secondary efficacy results while accounting for the remaining safety, confirmatory trial, and regulatory risks. Pricing, market penetration, launch timing, and the 10.25% discount rate remain unchanged.
Valuation Update
AER’s product-level risk-adjusted net present value model now implies an illustrative value of $20.00 per share, up from $16.40 at initiation. The higher modeled probability of success for HLP003 drives the revision. Dilution from recent equity issuance partly offsets the increase on a per-share basis.
Valuation Summary
- Illustrative Valuation
- $20.00
- Market Price at Publication
- $7.67
- Methodology
- Risk-adjusted Net Present Value (rNPV)
AER raises the modeled probability of success for HLP003 from 60% to 75% and retains its prior commercial assumptions and 10.25% discount rate. The illustrative estimate reflects the assumptions detailed in the report and is provided for research purposes.
What to Watch
Helus expects topline results from EMBRACE in Q4 2027. The trial compares 8 mg and 16 mg doses with placebo and will provide a separate test of efficacy and safety. Longer-term data from EXTEND will help assess durability, retreatment, and safety. Helus is targeting a 2028 U.S. regulatory filing, contingent on the remaining clinical and regulatory work.
Helus also plans to start a Phase 2 monotherapy trial of HLP004 for generalized anxiety disorder in Q1 2027. The pace of operating cash use and the terms of any future financing remain important to the funding outlook.
Disclosure
Alliance Equity Research provides this research for informational and educational purposes. It is not investment advice, a recommendation, or an offer or solicitation to buy or sell securities. Please review the full report and AER Research Disclosures for additional information.

